Loading companies…
United States · Biotech
Gamgee develops personalized mRNA vaccines for dogs with cancer, designed from the genetic profile of each dog’s tumor.
Gamgee applies genomic analysis and mRNA vaccine design to veterinary cancer care. Its approach starts with an individual dog’s tumor and uses its molecular profile to inform a personalized vaccine. The company grew from founder Paul Conyngham’s effort to help his dog Rosie after standard treatments failed, and is translating that experience into a biotechnology program for dogs with cancer.
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed | $4M | Founders Fund — LeadArash Ferdowsi — ParticipantCeline Halioua — ParticipantGokul Rajaram — ParticipantY Combinator (YC) — Participant |